Enhanced platelet aggregation with TRAP-6 and collagen in platelet aggregometry in patients with venous thromboembolism

• Published in: Thrombosis research 2002-09, Vol.107 (6), p.325-328
• Main Authors: Weber, M, Gerdsen, F, Gutensohn, K, Schoder, V, Eifrig, B, Hossfeld, D.K
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biological and medical sciences; Blood and lymphatic vessels; Blood Coagulation Disorders - complications; Blood Platelet Disorders - complications; Cardiology. Vascular system; Case-Control Studies; Collagen - pharmacology; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Female; Humans; Male; Medical sciences; Middle Aged; Peptide Fragments - pharmacology; Platelet Aggregation - drug effects; Platelet aggregometry; Platelet hyperaggregability; Risk Factors; Statistics, Nonparametric; Sticky-platelet syndrome; Venous thromboembolism; Venous Thrombosis - blood; Venous Thrombosis - etiology
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/S0049-3848(02)00351-1

The role of platelet hyperaggregability as a possible risk factor for venous thromboembolism is not well defined. Some authors described enhanced maximal platelet aggregation in platelet aggregometry as a contributing factor for arterial and venous thrombosis. This syndrome has been termed “sticky-platelet syndrome” (SPS). The diagnosis of SPS is based on the demonstration of platelet hyperaggregability in aggregometry after stimulation with epinephrine (EPI) and/or adenosine diphosphate (ADP). We investigated platelet hyperaggregability in platelet-rich plasma (PRP) of patients ( n=34) with unexplained venous thromboembolism in comparison to healthy individuals ( n=53). For analysis, platelet aggregometry was performed and the influence of epinephrine, adenosine diphosphate, collagen (Coll) and thrombin receptor-activated peptide (TRAP-6) as agonist were determined. Compared to the control group, patients with venous thromboembolism showed an enhanced maximal platelet aggregation with low concentrations of TRAP-6 (2 μM) and collagen (0.05 μM). In contrast, we could not detect an increased platelet aggregation with EPI or ADP. Our results indicate that platelet hyperaggregability may represent an independent risk factor in patients with otherwise unexplained venous thromboembolism. In our study, low concentrations of TRAP-6 and collagen are superior to EPI and ADP to define platelet hyperreactivity in platelet aggregometry.